BinDeBio
China - ShenzhenBiotechnology
Focus: BinDeBio is a China-based cellular therapeutics biotech focused on CAR-T and TCR-T cell immunotherapy for oncology indications. The company operates as a pre-revenue biotech with a pipeline concentrated in early-stage hematologic and solid tumor programs.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About BinDeBio
AI assessmentNot HiringNo open roles listed right now. Follow BinDeBio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CART-meso cells
Pancreatic CancerClinical Trials (1)
NCT03638193Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
N/AHelp build intelligence for BinDeBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.